Navigation Links
Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs
Date:11/5/2008

. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include full-year net loss and net cash burn projections, as well as statements about the company's pandemic influenza and CMV vaccine programs, the company's Vaxfectin(R) adjuvant, and other independent and collaborative programs. Risks and uncertainties include whether Vical or others will continue development of the CMV vaccine, the pandemic influenza vaccine, the Vaxfectin(R) adjuvant, or any other independent or collaborative programs; whether Vical will announce results of the Phase 2 CMV vaccine interim analysis in the fourth quarter, if at all; whether Vical will be able to complete a mutually satisfactory definitive agreement with AnGes; whether preliminary H5N1 DNA vaccine Phase 1 clinical trial results will be confirmed upon further analysis or in larger studies; whether Vaxfectin(R) or other results in animal studies can be duplicated in human clinical trials; whether nonclinical results will advance to human clinical testing, and if so, whether such testing will be successful; whether commercial partners or collaborators will pursue additional Vaxfectin(R) applications; whether the company will achieve levels of revenues and control expenses to meet projected financial performance; whether any product candidates will be shown to be safe and efficacious in clinical trials; the timing of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; the dependence of the company on its col
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results
2. Vical to Present at Upcoming Investor Conferences
3. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
4. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
5. Vical to Present at UBS Global Life Sciences Conference
6. Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
7. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
8. Vical to Present at Upcoming Investor Conferences
9. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
10. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
11. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... 2014 Deep Research Report on Global and ... study on the current state of the Nano Silver ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:7/11/2014)... PALM BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ ... variety of high-quality peptides that are used solely in ... To honor two successful years in business, Maxim Peptide, ... LLC, has just launched a new and updated website ... the research blog section has been updated with fascinating ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
(Date:7/11/2014)... July 11, 2014 EPFL and ... the appointment of John P. Donoghue . The ... Geneva . The new Wyss ... in Geneva , has named as ... John P. Donoghue , founder of Brown University,s ...
Breaking Biology Technology:2014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3
... Palatin Technologies, Inc. (NYSE Amex: PTN ... clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor ... the treatment of obesity. AZD2820 is a clinical candidate ... Palatin Technologies. Obesity is a global problem, ...
... 4, 2011   ReportsnReports announces ... Hospital-Acquired Infections (HAI) Diagnostics Market in its store ... for Alternatives to Needle-Based Systems for Vaccine and Biologics ... a focal point of competition within the pharmaceutical industry. The ...
... coatings devised by researchers from the National Institute of ... conventional flame retardants used in the polyurethane foam of ... and perhaps by as much as 1,130 percent. ... Polymer ,* suggest that significant fire-safety advantages can be ...
Cached Biology Technology:Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 2ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 3ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports 4Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:7/10/2014)... 2, 2014  Unisys Corporation,s (NYSE: UIS ) ... N.V., today announced that it has been selected by the ... a new Basic Provision Biometrics solution for penitentiaries across ... the contract with a solution based on its open standards-based ... of the contract is up to seven years, with the ...
(Date:7/10/2014)... SHELTON, Conn. , July 2, 2014 NXT-ID, Inc., ... market, reports that CEO Mr. Gino Pereira was ... radio show in Tampa Florida . Mr. ... radio host Cedric Harris and how the Wocket™ ... secure alternative.  Cedric Harris tells ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) has ... Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, ... to their offering http://photos.prnewswire.com/prnh/20130307/600769 ... Sensing Market to Grow Exponentially. Touch-less sensing applications ... companies were unable to leverage this technology due ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... The ability to shrink laboratory-scale processes to automated ... example, inexpensive and highly portable devices that process ... anthrax are needed by the U.S. military and ... of "lab-on-a-chip" technology is the need for miniaturized ...
... from reproductive biologists at the University of Massachusetts Amherst, with ... sperm capacitation that may one day improve success rates of ... problems, and may eventually lead to a male contraceptive. ... down the road, says Pablo Visconti, lead UMass Amherst author, ...
... review suggests that omega-3 fatty acids taken in excess could ... standards based on the best available evidence need to be ... years ago may not be as clear cut as we ... Public Health and Human Sciences and a coauthor on the ...
Cached Biology News:Super-thin membranes clear the way for chip-sized pumps 2Reproductive biologists move in vitro fertilization knowledge forward 2Reproductive biologists move in vitro fertilization knowledge forward 3Excess omega-3 fatty acids could lead to negative health effects 2Excess omega-3 fatty acids could lead to negative health effects 3
... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
... perform 96 assays on four slides. The ... slides with 96 (6mm x 7mm) individual ... expression, or screening analysis studies. Unlike other ... gasket, eliminating the presence of contaminating adhesives. ...
... with sequence siTrio siRNA --- a ... target gene of interestis our most popular product. ... 75% knockdown of your target gene when used ... and confirmation of optimal transfection with one of ...
... Macro-Prep ion exchange media are rigid ... allows high flow rates at moderate pressures, ... ionic sites, and the hydrophilic matrix reduces ... a high-capacity strong anion exchanger with very ...
Biology Products: